BioSpace

Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients

Post hoc analyses in women divided by menopausal status show how Novo’s next-generation GLP-1 drug affects key cohorts of ...
BioSpace

Danaher Reports Third Quarter 2026 Results

Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026. All results in this release reflect only ...
BioSpace

F2G and Shionogi Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome® Followed by Standard of Care in I…

These data will be submitted to regulatory authorities in the U.S. by F2G and in Europe and Asia by Shionogi. F2G anticipates ...
BioSpace

Syntax Bio Programs Stem Cells Toward Pancreatic Beta Cells in Four Days

New Cellgorithm™ data presented at ISSCR symposium indicates faster, scalable cell programming and add to Syntax Bio’s ...
BioSpace

Felix Becomes Canada’s First Virtual Care Provider to Offer Galleri® Multi-Cancer Early Detection Test Through its Expanded Longevity Program

Felix Health today announced it will offer Galleri ®, GRAIL's multi-cancer early detection test, through its virtual care ...
BioSpace

Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment

Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone ...
BioSpace

Coloplast A/S - FY 2025/26 Earnings Release - Invitation for conference call on 3 November 2026 at 11.00am CET

Tuesday, 3 November 2026 at 11.00 - 12.00am CET In connection with the publication of Coloplast’s financial results for FY ...
BioSpace

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month ...
BioSpace

Bioxodes BIOX-101 Phase 2a data show statistically significant reduction in perihematomal edema growth in intracerebral hemorrhage

Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of ...
BioSpace

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while ...
BioSpace

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September ...
BioSpace

Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting

Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed "This post ...